Size: | Price | Quantity | |
---|---|---|---|
10 mg | $68.00 | ||
50 mg | $200.00 |
Formoterol hemifumarate (43229-80-7) is a potent, long-acting agonist specific to β2 (Ki = 7.6 nM), but not β1 (Ki > 2.6 µM), adrenergic receptors in trachea (pD2 = 9.3) over atrium (pD2 = 7.0).1,2 Reduces adhesion and superoxide anion production in cultured activated eosinophils.3 Reverses cachexia in rats and mice via inhibition of the ATP-ubiquitin-dependent proteolytic system.4 Rescues LPS-induced motor function deficits and nigrostriatal dopamine loss in a rat model of Parkinson’s.5 Clinically useful for respiratory diseases.
References:
1) Anderson et al. (1993), Formoterol: pharmacology, molecular basis of agonism and mechanism of long duration of a highly potent and selective beta 2-adrenoceptor agonist bronchodilator; Life Sciences, 52 2145
2) Teng et al. (2005), Structure-activity relationship study of novel necroptosis inhibitors; Bioorg. Med. Chem. Lett., 15 5039
3) Noguchi et al. (2015), Effect of beta2-adrenergic agonist on eosinophil adhesion, superoxide anion generation, and degranulation; Allergol. Int., 64 S46
4)Busquets et al. (2004), Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting; Cancer Res., 64 6725
5) O’Neill et al. (2020), Pharmacological targeting of ß2-adrenoceptors is neuroprotective in the LPS inflammatory rat model of Parkinson’s disease; Br. J. Pharmacol., 177 282
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
Formoterol hemifumarate (43229-80-7) is a potent, long-acting agonist specific to β2 (Ki = 7.6 nM), but not β1 (Ki > 2.6 µM), adrenergic receptors in trachea (pD2 = 9.3) over atrium (pD2 = 7.0).1,2 Reduces adhesion and superoxide anion production in cultured activated eosinophils.3 Reverses cachexia in rats and mice via inhibition of the ATP-ubiquitin-dependent proteolytic system.4 Rescues LPS-induced motor function deficits and nigrostriatal dopamine loss in a rat model of Parkinson’s.5 Clinically useful for respiratory diseases.
References:
1) Anderson et al. (1993), Formoterol: pharmacology, molecular basis of agonism and mechanism of long duration of a highly potent and selective beta 2-adrenoceptor agonist bronchodilator; Life Sciences, 52 2145
2) Teng et al. (2005), Structure-activity relationship study of novel necroptosis inhibitors; Bioorg. Med. Chem. Lett., 15 5039
3) Noguchi et al. (2015), Effect of beta2-adrenergic agonist on eosinophil adhesion, superoxide anion generation, and degranulation; Allergol. Int., 64 S46
4)Busquets et al. (2004), Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting; Cancer Res., 64 6725
5) O’Neill et al. (2020), Pharmacological targeting of ß2-adrenoceptors is neuroprotective in the LPS inflammatory rat model of Parkinson’s disease; Br. J. Pharmacol., 177 282
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
For Postdoc
Customers!
Website Created by Advanta Advertising LLC.